| CD150 association with either the SH2-containing inositol phosphatase or the SH2-containing protein tyrosine phosphatase is regulated by the adaptor protein SH2D1A LM Shlapatska, SV Mikhalap, AG Berdova, OM Zelensky, TJ Yun, ... The Journal of Immunology 166 (9), 5480-5487, 2001 | 291 | 2001 |
| CDw150 associates with src-homology 2-containing inositol phosphatase and modulates CD95-mediated apoptosis SV Mikhalap, LM Shlapatska, AG Berdova, CL Law, EA Clark, ... The Journal of Immunology 162 (10), 5719-5727, 1999 | 142 | 1999 |
| The adaptor protein SH2D1A regulates signaling through CD150 (SLAM) in B cells SV Mikhalap, LM Shlapatska, OV Yurchenko, MY Yurchenko, GG Berdova, ... Blood 104 (13), 4063-4070, 2004 | 66 | 2004 |
| The multilevel regulation of CD95 signaling outcome M Yurchenko, LM Shlapatska, SP Sidorenko Experimental oncology, 2012 | 39 | 2012 |
| CD150 regulates JNK1/2 activation in normal and Hodgkin's lymphoma B cells MY Yurchenko, LM Kovalevska, LM Shlapatska, GG Berdova, EA Clark, ... Immunology and cell biology 88 (5), 565-574, 2010 | 36 | 2010 |
| Differential expression of PKD1 and PKD2 in gastric cancer and analysis of PKD1 and PKD2 function in the model system MY Shabelnik, LM Kovalevska, MY Yurchenko, LM Shlapatska, ... Experimental oncology, 2011 | 33 | 2011 |
| Monoclonal antibodies of IPO series against B cell differentiation antigens in leukemia and lymphoma immunophenotyping. SP Sidorenko, EP Vetrova, OV Yurchenko, AG Berdova, LN Shlapatskaya, ... Neoplasma 39 (1), 3-9, 1992 | 31 | 1992 |
| Immunohistochemical studies of protein kinase D (PKD) 2 expression in malignant human lymphomas LM Kovalevska, OV Yurchenko, LM Shlapatska, GG Berdova, ... Exp Oncol 28 (3), 225-230, 2006 | 26 | 2006 |
| Differential expression of CD150/SLAMF1 in normal and malignant B cells on the different stages of maturation IM Gordiienko, LM Shlapatska, LM Kovalevska, SP Sidorenko Experimental oncology, 2016 | 25 | 2016 |
| CD150-mediated Akt signalling pathway in normal and malignant B cells M Yurchenko, LM Shlapatska, OL Romanets, D Ganshevskiy, E Kashuba, ... Experimental Oncology, 2011 | 23 | 2011 |
| SLAMF1/CD150 in hematologic malignancies: silent marker or active player? I Gordiienko, L Shlapatska, L Kovalevska, SP Sidorenko Clinical Immunology 204, 14-22, 2019 | 22 | 2019 |
| The interplay of CD150 and CD180 receptor pathways contribute to the pathobiology of chronic lymphocytic leukemia B cells by selective inhibition of Akt and MAPK signaling I Gordiienko, L Shlapatska, V Kholodniuk, L Sklyarenko, DF Gluzman, ... PloS one 12 (10), e0185940, 2017 | 21 | 2017 |
| Expression of CD150 in tumors of the central nervous system: identification of a novel isoform O Romanets-Korbut, AM Najakshin, M Yurchenko, TA Malysheva, ... PLoS One 10 (2), e0118302, 2015 | 21 | 2015 |
| The role of CD150-SH2D1A association in CD150 signaling in Hodgkin’s lymphoma cell lines MY Yurchenko, EV Kashuba, LM Shlapatska, SA Sivkovich, SP Sidorenko Exp Oncol 27 (1), 24-30, 2005 | 16 | 2005 |
| Immunohistochemical studies of CD150 expression in some human tumors ИИ ЭКСПРЕССИИ Experimental Oncology 25 (3), 186-190, 2003 | 11 | 2003 |
| Intrinsic defect in B-lymphoblastoid cell lines from patients with X-linked lymphoproliferative disease type 1. II. receptor-mediated Akt/PKB and ERK1/2 activation and … LM Shlapatska, LM Kovalevska, IM Gordiienko, SP Sidorenko Experimental oncology, 2014 | 10 | 2014 |
| Signal transduction pathways in Burkitt’s lymphoma cell lines BL41 and DG75 with different sensitivity to doxorubicin LM Shlapatska, GG Berdova, LM Kovalevska, GI Kulyk, G Klein, ... Exp Oncol 26 (3), 210-216, 2004 | 10 | 2004 |
| CD150 and CD180 are involved in regulation of transcription factors expression in chronic lymphocytic leukemia cells IM Gordiienko, LM Shlapatska, VM Kholodniuk, LM Kovalevska, ... Experimental oncology, 2017 | 8 | 2017 |
| CD150 and CD180 are negative regulators of IL-10 expression and secretion in chronic lymphocytic leukemia B cells. V Shcherbina, I Gordiienko, L Shlapatska, D Gluzman, S Sidorenko Neoplasma 68 (4), 2021 | 6 | 2021 |
| Sensitivity of chronic lymphocytic leukemia cells to chemotherapeutic drugs ex vivo depends on expression status of cell surface receptors V Shcherbina, I Gordiienko, L Shlapatska, T Ivanivska, S Sidorenko Experimental Oncology 42 (1), 16-24, 2020 | 6 | 2020 |
